Scrip Cardiovascular

‘This Is A Global Problem’ – Chair Keon Sets Out IGBA’s Priorities For 2026

Dave Wallace — Thu, 19 Mar 2026 14:57:14 +0000

At the start of this year, Jim Keon – longtime president of the Canadian Generic Pharmaceutical Association and Biosimilars Canada – was named as the 2026 chair of the International Generic and Bios

Cipla Secures 2033 US Pedmark Generic Entry Under Settlement Agreement

Dean Rudge — Tue, 17 Mar 2026 15:00:37 +0000

Cipla has secured a US market entry date as early as September 2033 for its generic version of Fennec Pharmaceuticals’ Pedmark (sodium thiosulfate) intravenous injectable, under a settlement agreement

Ascent Fails On US Myrbetriq Challenge As Court Upholds Astellas Mirabegron Patents

Dean Rudge — Tue, 17 Mar 2026 11:53:43 +0000

Ascent Pharmaceuticals has lost its bid to clear the way for a US generic version of Astellas’s Myrbetriq (mirabegron), after a US district court ruled that the company’s proposed abbreviated new drug

‘Our Case Is About Standing Up To Patent Abuse’ – Sandoz Appeals Amgen Etanercept Antitrust Ruling

Dave Wallace — Mon, 16 Mar 2026 13:48:08 +0000

In the latest development in Sandoz’s long-running US legal battles with Amgen over Enbrel (etanercept), the biosimilars firm has made it clear that it is not going down without a fight. Seeming deter

Updated: Genentech Targets Biocon In USITC Case Over Perjeta Biosimilar Imports

Dean Rudge — Wed, 11 Mar 2026 14:21:43 +0000

Biocon and several of its biologics subsidiaries have been named in a complaint filed with the US International Trade Commission alleging infringement related to biosimilars of Roche’s blockbuster HER

Actelion Settles Tracleer Antitrust Case For $65m Ahead Of Trial

Dean Rudge — Tue, 10 Mar 2026 15:13:11 +0000

Johnson & Johnson’s Actelion Pharmaceuticals has agreed to pay $65m to settle US antitrust claims accusing the companies of blocking generic competition to its pulmonary arterial hypertension trea

Hikma Gets Backing Of US Solicitor General As Supreme Court Considers Skinny-Label Dispute

Dave Wallace — Wed, 04 Mar 2026 15:47:53 +0000

As the Supreme Court prepares to review long-running litigation between Hikma and Amarin over Vascepa (icosapent ethyl) and skinny-label generics – see previous coverage for full details of the case

Lessons On The Art Of Lobbying At AAM’s Access! 2026

Dave Wallace — Fri, 27 Feb 2026 13:48:02 +0000

When asked by Mark Ratner, the US Association for Accessible Medicines’ senior vice president for government affairs, to provide a single word to summarize the current political environment on Capitol

Teva’s US Korlym Infringement Victory Is Upheld On Appeal

Dean Rudge — Tue, 24 Feb 2026 12:54:20 +0000

Teva has secured a decisive appellate victory in its long-running US Hatch-Waxman dispute with Corcept Therapeutics, after the US Court of Appeals for the Federal Circuit affirmed a New Jersey distric

Sandoz Mulls Appeal As US Court Dismisses Amgen Enbrel Antitrust Complaint

Dave Wallace — Fri, 20 Feb 2026 12:14:10 +0000

When it comes to the biggest interval between a US biosimilar being approved and being able to launch, Sandoz holds the record. Its Erelzi (etanercept-szzs) rival to Amgen’s Enbrel was approved by the

Teva And GSK Settle Skinny-Label Dispute

Dave Wallace — Fri, 13 Feb 2026 11:32:56 +0000

Teva and GSK have reached a settlement resolving long-running US litigation revolving around Teva’s “skinny label” generic version of the originator’s Coreg (carvedilol). A Delaware district court fil

Win Or Loss? Zydus Follows Lupin In Mirabegron Suit Settlement With Astellas

Vibha Ravi — Thu, 12 Feb 2026 11:39:05 +0000

Zydus Lifesciences has followed Lupin in settling US patent litigation on overactive bladder drug Myrbetriq (mirabegron) with an agreement to pay Astellas Pharma $120m and a prepaid per unit licensing

Lupin Strikes $90m Settlement With Astellas On Myrbetriq

Vibha Ravi — Tue, 10 Feb 2026 15:28:55 +0000

Just before the next round of litigation in the US between Astellas Pharma and generics firms over Myrbetriq (mirabegron), the Japanese major has reached a settlement with Lupin that allows the Indian

Organon And Henlius Settle US Perjeta Litigation

Dave Wallace — Tue, 10 Feb 2026 11:30:27 +0000

Organon and Henlius have cleared a major obstacle to marketing their Perjeta (pertuzumab) biosimilar in the US by settling patent litigation with originator Roche over their Poherdy (pertuzumab-dpzb)

Sandoz And Former Parent Novartis Hit With Fresh US Generic Price-Fixing Suit

Dean Rudge — Mon, 09 Feb 2026 11:49:17 +0000

A coalition of dozens of US states and territories has sued Novartis and its former generics division, Sandoz, alleging that the companies participated in a years-long conspiracy to fix prices, alloca

‘These Decisions Created A Lot Of Uncertainty’ – Why The Supreme Court’s Skinny-Label Ruling Matters

Dave Wallace — Wed, 04 Feb 2026 11:31:34 +0000

The US Supreme Court’s recent announcement that it would review long-running litigation between Hikma and Amarin over Vascepa (icosapent ethyl) – revolving around induced infringement and “section v

BMS To Continue Legal Action As Zydus Launches First Cut-Price Nivolumab Biosimilar In India

Vibha Ravi — Fri, 23 Jan 2026 16:18:07 +0000

Bristol Myers Squibb will continue seeking legal recourse while Zydus Lifesciences has launched the world’s first cut-price nivolumab biosimilar in India following a Delhi high court division bench ru

Amarin Hits Back Over SCOTUS Skinny-Label Review

Dave Wallace — Thu, 22 Jan 2026 11:31:21 +0000

Amarin has hit back at Hikma after the US Supreme Court recently agreed to review the pair’s long-running induced infringement litigation with Amarin over Vascepa (icosapent ethyl) and “section viii

US Supreme Court Will Review Skinny-Label Litigation

Dave Wallace — Mon, 19 Jan 2026 13:56:48 +0000

Hikma has been granted its wish: the US Supreme Court has agreed to review its long-running induced infringement litigation with Amarin over Vascepa (icosapent ethyl). The Supreme Court’s decision to

Stada, Dr Reddy’s And Zentiva Sink Cabazitaxel Patent At UPC

Dean Rudge — Thu, 18 Dec 2025 11:30:24 +0000

A trio of generics manufacturers have strengthened their position in the European cabazitaxel market after the Unified Patent Court ruled that a publicly disclosed Phase III clinical trial fatally und